Heading East: Biopharma International Expansion to China and Asia
December 17, 2018
China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending. While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike.
Download Full Comments Below
Biopharma International Expansion To China And Asia For Web
The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
China’s rapidly growing economy has helped drive unprecedented growth in its healthcare market. Driven by pro-innovation and pro-biotechnology policy trends, China is becoming a prime market for biopharmaceutical companies globally; nearly 90% of the firms in L.E.K.’s biopharma survey expressed interest in a China expansion. Furthermore, Asia, not only contains 60 percent of the world’s population, it also accounts for 30% of the world’s GDP and pharmaceutical spending.
While recent policy reforms in China are expected to create enormous opportunities for global firms, China nevertheless remains a complicated market for emerging biotech companies and multinational corporations alike.